Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Lenalidomide treatment of POEMS syndrome

Arnaud Jaccard • 15 Oct 2019
IMW 2019
Multiple Myeloma Dexamethasone Lenalidomide

Arnaud Jaccard, MD, PhD, University Hospital Limoges Dupuytren, Limoges, France, elaborates on his study which investigated the efficacy and safety of lenalidomide when treating POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal plasmaproliferative disorder & Skin changes) syndrome and provides an overview of the initial results. This interview was recorded at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Related Videos

1:15
Using MRD to guide treatment decisions in myeloma
Karthik Ramasamy • 28 Apr 2024
0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals